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ABSTRACT 
 
Based on its shedding and binding activities, the disintegrin and metalloprotease 12 
(ADAM12) has been implicated in cell signaling. Here, we investigate the intracellular 
protein interaction network of the transmembrane ADAM12L variant using an integrative 
approach and we identify the integrin-linked kinase (ILK) as a new partner for ADAM12L 
cellular functions. We demonstrate that ADAM12L coimmunoprecipitates with ILK in cells 
and that its cytoplasmic tail is required for this interaction. In human cultured hepatic stellate 
cells (HSCs), which express high levels of endogenous ADAM12L and ILK, the two proteins 
are redistributed to focal adhesions upon stimulation of a β1 integrin-dependent pathway. We 
show that down-regulation of ADAM12L in HSCs leads to cytoskeletal disorganization and 
loss of adhesion. Conversely, up-regulation of ADAM12L induces the Akt Ser473 
phosphorylation-dependent survival pathway via stimulation of β1 integrins and activation of 
PI3K. Depletion of ILK inhibits this effect, which is independent of ADAM12L proteolytic 
activity and involves its cytoplasmic domain. We further demonstrate that overexpression of 
ADAM12L promotes kinase activity from ILK immunoprecipitates. Our data suggest a new 
role for ADAM12L in mediating the functional association of ILK with β1 integrin to 
regulate cell adhesion/survival through a PI3K/Akt signaling pathway. 
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INTRODUCTION 
 
ADAM12 is a member of the disintegrin and metalloprotease (ADAM) protein family 
whose members are cell-surface multi-domain proteins involved in ectodomain shedding, 
adhesion, and signaling activities (Edwards et al., 2008). ADAM archetypes are 
transmembrane proteins that contain propeptide, extracellular metalloprotease, disintegrin-
like, cystein-rich, epidermal growth factor (EGF)-like, transmembrane and cytoplasmic 
domains.  
In humans, the expression of ADAM12 is mainly associated with adult skeletal, cardiac 
and smooth muscle and is dramatically increased in several pathologies, including cancer 
(Kveiborg et al., 2008). Within tissues, ADAM12 up-regulation has been described in both 
cancer and stromal cells and increased urine protein levels were also reported in patients with 
breast or bladder tumors. Genome-wide analyses of human tumors identified ADAM12 as a 
new candidate cancer gene (Sjoblom et al., 2006) and it is now considered as a prognosis 
marker for human bladder cancer (Roy et al., 2004; Frohlich et al., 2006) and breast cancer 
(Pories et al., 2008; Narita et al., 2010). In support of its involvement in cancer, ADAM12 
was shown to regulate tumor progression in genetically modified mouse models. However, 
the mechanism involved remains unclear (Kveiborg et al., 2005; Peduto et al., 2006).  
The human ADAM12 gene is expressed as two alternatively spliced transcripts that give 
rise to transmembrane ADAM12L and secreted ADAM12S forms, the latter lacking the 
transmembrane and cytoplasmic domains. Both ADAM12 variants can act as proteases and 
have been shown to cleave IGFBP3 and IGFBP5 (Loechel et al., 2000; Shi et al., 2000), EGF 
receptor ligands (Asakura et al., 2002; Horiuchi et al., 2007), Notch ligand Delta-like 1 
(Dyczynska et al., 2007) and placental oxytocinase (Ito et al., 2004). Besides its 
metalloprotease activity, the membrane-anchored ADAM12L long form is involved in cell-
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cell and cell-matrix interaction via its binding to cell-surface molecules that include integrins 
(Eto et al., 2000; Kawaguchi et al., 2003), syndecans (Iba et al., 2000) and type II TGF-β 
receptor (Atfi et al., 2007). However ADAM12L is not constitutively addressed to the 
membrane and its distribution at the cell surface is a dynamic process that requires PKCε 
activation (Sundberg et al., 2004), recruitment of RACK1 (Bourd-Boittin et al., 2008) and c-
Src activity (Stautz et al., 2010). All these events take place in response to external cell 
stimulation such as integrin engagement and depend on the intracellular domain of 
ADAM12L since its truncation prevents translocation of the protein (Hougaard et al., 2000). 
The cytoplasmic tail of ADAM12 has been shown to physically interact with several 
signaling proteins, including the Src-non receptor tyrosine kinases, c-Src and YES (Suzuki et 
al., 2000), the adapter proteins Grb2 (Suzuki et al., 2000) and Fish (Abram et al., 2003), the 
regulatory subunit of phosphatidylinositol 3-kinase, p85α (Asakura et al., 2002), the 
cytoplasmic PACSIN3 phosphoprotein (Mori et al., 2003), eve-1, an EEN binding protein 
implicated in shedding activity (Tanaka et al., 2004) and two actin-related proteins, α-actinin-
1 and -2 (Galliano et al., 2000; Cao et al., 2001). This complex protein interaction network 
contributes to the regulation of ADAM12L translocation and function and might in turn play 
a pivotal role in the coordination of cell signaling and responses to the microenvironment. 
In liver cancer, we have previously demonstrated that up-regulation of ADAM12 
expression was associated with the activation of hepatic stellate cells (HSCs) (Le Pabic et al., 
2003) and the regulation of the TGF-β signaling pathway (Atfi et al., 2007). In addition, our 
data showed that type I collagen, the major collagen in fibrosis tissue, promoted the 
localization of ADAM12 to the surface of HSCs through a β1 integrin-dependent mechanism 
(Bourd-Boittin et al., 2008). In this study, we have explored the ADAM12L protein 
interaction network using an integrative data-mining approach. We identify the Integrin-
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Linked Kinase (ILK), a kinase associated with human malignancies, as a new potential 
partner for ADAM12L. Our results demonstrate that ADAM12L co-immunoprecipitates with 
ILK and that stimulation of HSCs by type I collagen induces the recruitment of both proteins 
to focal adhesion-like structures. We show that down-regulation of ADAM12L leads to a loss 
of cell adhesion while over-expression induces the Akt-dependent survival pathway and 
increases the kinase activity of ILK immunoprecipitates. We propose that ADAM12 plays a 
major role in adhesion-cell survival processes through enhancement of the β1 
integrin/ILK/Akt signaling pathway. 
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RESULTS 
 
An ADAM12 protein interaction network as part of the integrin signaling network 
The interaction of ADAM12L with numerous receptors and intracellular signal 
mediators (listed in Table 1) suggests that it could act as a docking/signaling protein. Using 
the STRING database to extract direct (physical) and indirect (functional) associations 
between proteins, we built the ADAM12L protein interaction network shown in Figure 1. The 
high level of interconnections suggests strong associations with the same biological functions. 
The connectivity of the graph was next enriched by adding five known interactions not yet 
incorporated in the database, between ADAM12 and TGFBR2, GNB2L1, PRKCE and 
PRKCD, and between Src and TGFBR2. Interestingly, all known proteins identified as 
ADAM12-binding proteins were previously shown to be associated with Src. These include 
the four SH3 domain-containing proteins SH3D19, SH3PXD2A, YES1 and PACSIN3. In 
addition ADAM12 and Src both connect to the same sub-network in which the integrin 
signaling pathway stands out. Because engagement of β1 integrin (ITGB1) by external stimuli 
has been recently associated with the Src-mediated modulation of ADAM12 subcellular 
distribution (Stautz et al., 2010), we sought to investigate a possible interaction between 
ADAM12 and a major functional partner of integrins, ILK. Our rationale was that ILK 
directly binds to integrins in response to stimulation by the microenvironment, suggesting a 
pivotal role in signal transduction that might implicate ADAM12. 
 
ADAM12 interacts with the ILK integrin-linked kinase 
To test this hypothesis, we first investigated whether ADAM12 interacts with ILK in 
Cos7 cells, which do not express endogenous ADAM12. Endogenous ILK was 
immunoprecipitated from extracts of cells transfected with ADAM12L. As shown in Figure 
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2A, both pro- and processed ADAM12, the 110 and 90 kDa forms, respectively, were 
expressed in Cos7 cells (left panel) and co-immunoprecipitated with ILK (center panel). The 
reverse immunoprecipitation was performed using a mix of ADAM12 monoclonal antibodies 
and blotted for ILK (Figure 2A, right panel). The co-immunoprecipitation of ILK and 
ADAM12 was confirmed using transfection of V5-tagged ILK in either Cos7 cells transfected 
with ADAM12 or in the LX2 hepatic stellate cell (HSC) line, which expresses low 
endogenous ADAM12 levels (Supplementary Figure S1). To show whether the interaction 
between ADAM12 and ILK occurs under physiological conditions, we used primary cultures 
of HSCs isolated from human liver tissues. Cell culture mimics the HSC activation process, 
which consists in the transition from a quiescent to a fibrogenic state. This is accompanied by 
increased expression of ADAM12 and ILK, as previously described in chronic liver diseases 
(Le Pabic et al., 2003; Zhang et al., 2006). The expression of endogenous ADAM12L in 
activated HSCs is shown in Figure 2B (left panel). When immunoprecipitation was performed 
using ILK antibodies, ADAM12/ILK complexes were clearly detected in cell extracts (Figure 
2B, center panel). The reverse immunoprecipitation using ADAM12 antibodies confirmed the 
endogenous interaction of ADAM12 and ILK (Figure 2B, right panel).  
To identify the domain of ADAM12 that is required for interaction with ILK, Cos7 cells 
were transfected with ADAM12L, with a truncated form lacking the cytoplasmic domain 
(ADAM12-∆cyt) or with the ADAM12S short form. As shown in Figure 2C, 
immunoprecipitation of ILK led to the recovery of high amounts of ADAM12L. In contrast, 
neither ADAM12L-∆cyt (90 kDa) nor ADAM12S (90 kDa and 68 kDa for the precursor and 
processed forms, respectively) were detected in immunoprecipitates, pointing out the 
implication of the ADAM12 cytoplasmic domain in the interaction with ILK. Because 
disintegrin and cystein-rich domains are present in ADAM12L-∆cyt and ADAM12S and 
have been reported to interact with integrins (Eto et al., 2000; Kawaguchi et al., 2003; 
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Thodeti et al., 2003; Zhao et al., 2004; Huang et al., 2005; Lafuste et al., 2005), the lack of 
recovery of ADAM12L-∆cyt and ADAM12S in ILK immunoprecipitates suggests that 
integrins do not mediate the interaction of ADAM12 and ILK. In addition, we investigated 
the presence of PINCH and parvin in ILK-ADAM12 immune complexes isolated from cell 
extracts as ILK has been linked to PINCH and parvin proteins in forming the IPP complex 
(Legate et al., 2006). As expected, both proteins were detected in ILK immunoprecipitates 
(Figure 2D), suggesting that the interaction of ADAM12 and ILK takes place within IPP 
complexes.  
To rule out the possible implication of additional proteins, we next investigated 
ADAM12/ILK interactions using recombinant proteins in in vitro binding assays. ILK was 
expressed as a GST fusion protein and purified on glutathione-agarose beads before removal 
of the GST tag (recILK). We then performed pull-down assays by incubating recILK with 
purified His-tagged ADAM12 variants. As shown in Figure 2E, recILK only bound full-
length ADAM12L, demonstrating an association that is both direct and specific. These results 
provide strong evidence for a direct interaction of the cytoplasmic domain of ADAM12L with 
ILK in cells. To investigate the functional relevance of the interaction between ADAM12 and 
ILK, we next explored the localization of both proteins in HSCs.  
 
ADAM12 and ILK are recruited to focal adhesions upon β1 integrin stimulation 
We have previously shown that ADAM12 is stored in the cytoplasm and translocated to 
the membrane of HSCs upon stimulation by type I collagen (Bourd-Boittin et al., 2008). To 
investigate the dynamics of the interaction between ADAM12 and ILK, we immunolocalized 
ADAM12 and ILK in HSCs stimulated or not by type I collagen. As shown in Figure 3A, 
immunostained ILK and ADAM12 were strongly redistributed to the cell surface when HSCs 
were plated on type I collagen. Similarly, in stimulated HSCs, ADAM12 co-localized with β1 
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integrin (Figure 3B) and vinculin (Figure 3C), a cytoskeletal focal adhesion protein involved 
in linkage of integrin adhesion molecules to the actin cytoskeleton. In agreement with these 
observations, the colocalization of ILK with β1 integrin was increased upon stimulation by 
type I collagen (Figure 3D). We further demonstrated the involvement of β1 integrin in the 
redistribution of ILK and ADAM12 to focal adhesions by using anti-β1 integrin blocking 
antibodies. As shown in Figure 3E, preincubation of HSCs with blocking antibodies inhibited 
the translocation of ADAM12 to the focal adhesions. These results suggest that activation of 
the integrin pathway by type I collagen induces the recruitment of both ADAM12 and ILK to 
focal adhesions. 
 
ADAM12 modulates hepatic stellate cell adhesion 
Because ILK and ADAM12 are recruited to focal adhesions in stimulated HSCs (Figure 
3), and ILK has been previously associated with the fibrogenic phenotype of HSCs through 
its implication in cell adhesion (Shafiei and Rockey, 2006), we next asked whether expression 
for ADAM12 could affect cell adhesion. We performed ADAM12 siRNA knockdowns in 
human HSCs. After 48 hours of treatment, the steady-state levels of ADAM12 mRNA and 
proteins were significantly reduced in HSCs, indicating robust RNA interference efficiency 
(Figure 4A and B). Note that both the long and the short variants of ADAM12 were equally 
silenced while expression of type I collagen and TGF-β, the two fibrogenic markers of HSCs 
used as controls, was not modified. During the course of this analysis, we observed changes 
in cell spreading and we sought to examine the effect of ADAM12 on the cytoskeleton of 
HSCs by performing microscopy analysis of actin stress fibers (Figure 4C). Type I collagen 
induced prominent stress compared to control cultures on plastic dishes. In addition, we found 
that inhibition of ADAM12 expression led to a striking disorganization and retraction of 
stress fibers, suggesting major changes in cell spreading and adhesion processes. In line with 
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this conclusion, ADAM12 silencing in HSCs led to a significant decrease in adherent cells 
cultured on plastic dishes (26% + 2.5 and 40% +2.7 decrease at 24 and 48 hr, respectively, 
Figure 4D, left panel). Cultivating HSCs on type I collagen delayed this effect, probably by 
mobilizing more integrins. However, a significant reduction in adherent cells (-35.6% + 2.8) 
was observed at 48 hr under these growth conditions. In agreement with this observation, 
ADAM12-silenced cells plated onto either type I collagen, fibronectin or laminin, which 
engage different integrins, showed a reduced loss of cell adhesion compared to an albumin 
plating control (Figure 4D, right panel).  
The effect of ADAM12 silencing on cell adhesion was maximal at 48 hours. Over 
longer times, expression of ADAM12 resumed in HSCs transiently transfected with 
siADAM12 (Supplementary Figure S2A). Note that all cells recovered in the culture 
supernatants following transfection with ADAM12 siRNAs no longer expressed ADAM12. 
In addition, cell death was unaffected in HSCs transfected with siADAM12 (Supplementary 
Figure S2B). This conclusion is further supported by the demonstration that overexpression of 
ADAM12 in CHO cells treated with staurosporine or TNF-related apoptosis-inducing ligand 
(TRAIL) did not significantly protect cells against death (Supplementary Figure S3). Because 
ILK plays an important role in the regulation of cell proliferation and migration (McDonald et 
al., 2008), we also sought to explore how ADAM12 overexpression could modulate these 
effects. As shown in Supplementary Figure S4, ADAM12 induced a significant but slight 
increase in cell proliferation (Figure S4A) and migration (Figure S4B) suggesting a minor 
effect in these conditions.  
Based on the physical and functional association of endogenous ADAM12 and ILK in 
HSCs, we next explored which signaling pathway(s) might be involved in this effect.  
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Expression of ADAM12 reinforces the Akt signaling pathway 
Cell adhesion to the extracellular matrix is mediated by the integrin-stimulated ILK-
dependent pathway, which involves Protein Kinase B (Akt) and GSK-3. To examine whether 
expression of ADAM12 modulates Akt and GSK-3 activation, Cos7 cells were transfected 
with wild-type and mutants ADAM12 constructs for 48 hours and further plated on type I 
collagen-coated dishes. Phosphorylation of Akt and GSK-3 was examined by western blot 
analysis at the times indicated in Figure 5. Overexpression of ADAM12L significantly 
enhanced Akt and GSK-3 phosphorylation compared to cells transfected with an empty 
vector (Figure 5A). Interestingly, this induction was independent of the proteolytic activity of 
ADAM12L since the catalytically deficient ADAM12-E351Q mutant induced Akt and GSK-
3 phosphorylation to an extent similar to that of wild-type ADAM12L (Figure 5B). Neither 
the ADAM12-∆cyt truncated form nor the ADAM12S secreted form, which do not bind ILK 
(Figure 1D), could induce Akt and GSK-3 phosphorylation (Figure 5C), establishing that the 
effect of ADAM12L on the Akt signaling pathway is specific.  
To determine whether this stimulating effect was dependent on ILK and β1 integrin, we 
assessed the phosphorylation status of Akt in cells either silenced for ILK or pre-incubated 
with anti-β1 integrin blocking antibodies. Down-regulation of ILK expression (Figure 6A) or 
inhibition of β1 integrin (Figure 6B) both diminished Akt phosphorylation induced by 
overexpression of ADAM12L, demonstrating the implication of β1 integrin and ILK in 
mediating the effect of ADAM12L. In line with this conclusion, adhesion on type I collagen 
of HSCs, which express high basal levels of ADAM12L, induced a similar phosphorylation 
of Akt and GSK3 (Figure 6C).  
To further explore the molecular mechanisms underlying this novel modulation of the 
Akt pathway by ADAM12L, we next analyzed the involvement of PI3K, an upstream-acting 
kinase that regulates ILK activity (Delcommenne et al., 1998). For this purpose, we evaluated 
12 
 
the effects of two PI3K inhibitors, Wortmannin and LY294002, on Akt phosphorylation. 
Transfected cells were pre-incubated with the inhibitors prior to plating on type I collagen for 
60 min and Akt phosphorylation was analyzed by western blotting. As shown in Figure 6D, 
Wortmannin and LY294002 both blocked the ADAM12L-dependent induction of Akt 
phosphorylation, establishing the implication of PI3K activity in this phenomenon.  
Providing additional support for the role of ADAM12L in the promotion of the 
ILK/Akt-dependent pathway, ILK immunoprecipitates from extracts of cells overexpressing 
ADAM12L directly phosphorylated the downstream GSK-3 crosstide peptide substrate (CT-
GSK-3), while phosphorylation of CT-GSK-3 was very low in absence of ADAM12 (Figure 
7). This effect was correlated with the concentration of ADAM12L in cells (Figure 7A) and 
was specific to ADAM12L and dependent on ILK, since the phosphorylation of CT-GSK-3 in 
cells overexpressing ADAM12S was similar to that in control and in ILK-silenced cells 
(Figure 7B). Taken together, results of these experiments demonstrate that ADAM12L 
expression augments the Akt/GSK3 signaling pathway in response to microenvironment 
stimulation via a β1 integrin/PI3K/ILK-dependent pathway. 
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DISCUSSION 
 
Members of the ADAM protein family have emerged as important regulators of cell 
signaling, through shedding activities of membrane-anchored cytokines or growth factors. 
Besides ligand processing, ADAMs have been proposed to function as signal transmitters. In 
the present study, we used an in silico approach based on protein integrative annotation to 
explore the intracellular protein interaction network of the transmembrane variant of 
ADAM12, ADAM12L. The resulting highly connected graph suggests that integrin signaling 
plays a critical role in the ADAM12L network. In agreement with this observation, the 
dynamic association of ADAM12 with Src upon integrin engagement was recently suggested 
to exert cooperative signals for cell proliferation, migration, and invasion (Stautz et al., 
2010). In addition, a functional association of ADAM12 with integrin signaling has been 
previously implicated in the mesenchymal differentiation of adipocytes (Kawaguchi et al., 
2003) and myogenic cells (Lafuste et al., 2005), in cell adhesion and spreading (Thodeti et 
al., 2003; Zhao et al., 2004), migration (Huang et al., 2005) and invapodia formation 
(Albrechtsen et al., 2011). However the molecular mechanism linking ADAM12 to integrin 
signaling has remained unclear. We now provide evidence for the interaction of ADAM12 
with the integrin-linked kinase ILK and demonstrate the role of ADAM12 in enhancing the 
functionality of the ILK/Akt signaling pathway upon integrin stimulation. ILK is found in 
most cells within the IPP complex formed together with PINCH and Parvin (Legate et al., 
2006). Our co-immunoprecipitation experiments show that the ILK/ADAM12 interaction we 
report can occur within these complexes and without disrupting them, highlighting the 
acquisition of a new functionality for IPP as a function of ADAM12 recruitment. 
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Dynamic translocation of ADAM12 with ILK to focal adhesions 
In response to binding of integrins to matrix components, ILK associates with adaptor 
proteins and is recruited to nascent focal complexes enriched in docking and signaling 
proteins including vinculin (Legate and Fassler, 2009). In agreement with this dynamic 
translocation of ILK, we have previously reported that stimulation of integrin pathways by 
type I collagen induces the recruitment of ADAM12 to the membrane of hepatic stellate cells 
(Bourd-Boittin et al., 2008). We now demonstrate that, similar to ILK, ADAM12 is 
redistributed within vinculin-rich structures at the cell surface of HSCs stimulated by type 1 
collagen. This suggests that ADAM12 contributes to the dynamics of protein-complex 
formation at focal adhesions in HSCs. Transiently increased levels of ADAM12/β1 integrin-
containing complexes have been reported at the cell surface of pre-adipocytes (Kawaguchi et 
al., 2003). Interestingly, this study showed that forced expression of the ADAM12-∆cyto 
truncated protein, which spontaneously translocates to the membrane, also led to alterations 
of the actin cytoskeleton, cell adhesion and survival. These observations suggest that the 
cytoplasmic tail of ADAM12 is required to sustain these functions. In support of this 
hypothesis, our data show that ADAM12 silencing induces loss of HSC adhesion and that the 
cytoplasmic tail of ADAM12 is required for the ILK-dependent survival pathway that 
correlates with cell adhesion.  
 
Functional association of ADAM12 and ILK for Akt-dependent survival signaling 
Over the past several years, the in vivo and in vitro kinase activity of ILK has been 
widely debated and ILK has been suggested to function as an adaptor/scaffold protein (Lange 
et al., 2009; Maydan et al., 2010; Wickstrom et al., 2010; Fukuda et al., 2011; Hannigan et 
al., 2011). Nevertheless, the classical ILK-dependent pathway involves a PI3K-dependent 
integrin engagement that leads to the phosphorylation of downstream Akt and GSK-3 targets. 
15 
 
In addition, ILK properties can be modulated in vivo by complex protein interactions that 
result in activities triggered by the contextual environment, such as that found in cancer cells 
(Troussard et al., 2006). In line with this notion, our data demonstrate that ADAM12, a 
protein specifically expressed in activated HSCs during chronic liver disease, enhances the 
activity of the ILK/Akt pathway in response to β1 integrin activation by type I collagen, the 
main matrix component of liver fibrosis. These results are in agreement with the reported 
implication of ILK pathway activity in the Akt-dependent regulation of fibroblast survival 
upon integrin stimulation (Nho et al., 2005). 
The contextual association between ADAM12 and the ILK/Akt pathway is further 
supported by the correlation between ADAM12 and ILK expression. ADAM12 expression is 
associated with the undifferentiated proliferating state of mesenchymal cells such as 
chondrocytes in osteoarthritis (Okada et al., 2008), pre-adipocytes during high-fat diet-
induced obesity (Masaki et al., 2005), hepatic stellate cells in liver fibrosis (Le Pabic et al., 
2003), myoblasts during myogenic differentiation (Cao et al., 2003) and proliferating 
astroglial cells in injured brain (Baertling et al., 2010). It is also involved in the initial steps of 
pre-keratinocyte differentiation, where the absence of ADAM12 promotes migration, a 
differentiated feature of keratinocytes (Harsha et al., 2008; Oh et al., 2009). Similar to 
ADAM12, increased activation of the ILK/Akt pathway has been associated with cell 
proliferation (Persad and Dedhar, 2003). In contrast, ILK knockdown in chondrocytes 
(Grashoff et al., 2003), keratinocytes (Lorenz et al., 2007), fibroblasts (Sakai et al., 2003) and 
cortical cells (Niewmierzycka et al., 2005) is not associated with a decrease in Akt 
phosphorylation, suggesting that, in differentiated cells, ILK could signal through an Akt-
independent pathway. Taken together, these observations suggest that the specific expression 
of ADAM12 in proliferating undifferentiated mesenchymal-type cells might favor ILK/Akt 
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pathway activity, thereby promoting the survival signaling pathway that is classically 
associated with cell adhesion.  
 
Cooperative effects of ILK and ADAM12 in cancer 
The ubiquitously expressed ILK is involved in tissue homeostasis. Elevated expression 
of ILK has been observed in tumors with poor prognosis and has been proposed as a new 
therapeutic target (Hannigan et al., 2005). Similarly, ADAM12 expression is markedly 
increased in numerous human cancers (Kveiborg et al., 2008) and we have previously 
reported the association of ADAM12 expression with liver fibrosis and cancer (Le Pabic et 
al., 2003). In agreement with our results, ILK overexpression has also been shown to be 
associated with the activation of HSCs in liver fibrosis (Shafiei and Rockey, 2006; Zhang et 
al., 2006) and induction of ILK activity has been correlated with an increased activation of 
Akt in hepatocellular carcinomas (Peroukides et al., 2008). In line with these observations, 
the expression of ADAM12 in mammary-gland tumor cells was recently associated with 
increased cell proliferation and Akt phosphorylation levels (Frohlich et al., 2011). Similar to 
results reported in the present study, this effect was independent of the proteolytic activity of 
ADAM12, suggesting that the pro-tumorigenic effect of ADAM12 is mediated by the 
disintegrin and cystein-rich domains which interact with integrins (Eto et al., 2000; 
Kawaguchi et al., 2003; Thodeti et al., 2003; Zhao et al., 2004; Huang et al., 2005; Lafuste et 
al., 2005). Interestingly we have previously shown that these same domains also interact with 
the TβRII receptor of transforming growth factor TGF-β (Atfi et al., 2007), which affects cell 
survival and proliferation through a PI3K/Akt dependent pathway (Shin et al., 2001; Wilkes 
et al., 2005). These data reinforce the notion that ADAM12 might act as a scaffolding protein 
for integrin- and TGF-β receptor-dependent pathways, leading to the activation of 
PI3K/ILK/Akt signals and thereby affecting cancer cell survival. 
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In conclusion, results of this study, which identify ILK as a new ADAM12 partner, 
unravel a major aspect of the biological significance of the functional association of 
ADAM12 with the integrin signaling pathway. In addition, induction of the ILK/Akt pathway 
by ADAM12 suggests a potential role for this protein in cell adhesion and survival. 
According to this view, ADAM12 would act as a pivotal sensor implicated in the regulation 
of a microenvironment-dependent equilibrium between differentiation and proliferation. 
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MATERIAL AND METHODS 
 
Cell culture and transfection 
Human hepatic stellate cells (HSCs) were isolated from histologically normal specimens of 
partial hepatectomies from patients undergoing hepatic resection for liver metastases as 
previously described (Le Pabic et al., 2003). HSC and Cos7 cells were maintained in 
Dulbecco’s minimal essential medium supplemented with 10% fetal bovine serum (FBS). For 
all experiments, cultured HSCs were used between passages 4 and 10. When specified, cells 
were plated on collagen type I-coated dishes (BD Biosciences) or Permanox Lab-Tek® 
chamber slides™. HSCs were transfected using the AMAXA protocols and kits (Amaxa 
Biosystems, Cologne, Germany) according to the manufacturer’s instructions. In some 
experiments, cells were incubated either with PI3K inhibitors, 100 nM Wortmannin 
(Calbiochem, Darmstadt, Germany) or 10 µM LY294002 (Calbiochem), for 30 min or anti-
ITBG1-blocking antibodies (Santa-Cruz biotechnology, CA) for 30 min at 37°C under 
agitation without FBS. To knock down ADAM12 and ILK expression, synthetic double-
stranded ADAM12 siRNAs were purchased from Sigma. The expression vectors for 
ADAM12 and mutants thereof, including the complete deletion of the cytoplasmic tail 
(ADAM12-∆cyt) and the protease inactive mutant ADAM12-E351Q, were a gift from Dr. U. 
Wewer (Biotech Research & Innovation Centre (BRIC), University of Copenhagen). The 
expression vector for ILK was a gift from Dr. S. Dedhar (Department of Integrative 
Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada). 
 
Adhesion assays. Cell adhesion was measured using a trypsinization assay. Briefly, HSCs 
transfected with 2 nM non-targeted siRNA (Scr) or ADAM12L siRNA (siADAM12) were 
plated onto collagen type I dishes or on laminin, and fibronectin coated multiwell plates (BD 
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Biosciences) for indicated time in absence of serum. Cells were then treated with 0.5 ml of 
0.05% trypsin-EDTA for 4 min, detached cells were collected in media containing 10% 
serum and manually counted. Numbers of detached cells expressed as a percentage of total 
were determined in three independent experiments. Controls included uncoated and albumin 
(10mg/mL in PBS) coated dishes.  
 
Cell Proliferation and migration assays 
Cos7 cells were transfected with ADAM12 or control vectors and cultured for 48 hours. 
Cells were then trypsinized, equilibrated in medium for 1 hour at room temperature and 
plated on collagen type I-coated dishes. For cell proliferation assay, the medium was replaced 
with DMEM containing 2% FCS in the presence of 3[H]-thymidine and incubated for the 
indicated times. Cells were scraped in phosphate-buffered saline (PBS), sonicated for 10 min 
and treated with overnight with 30% trichloroacetic acid (TCA). Cell extracts were 
centrifugated and the pellets homogenized in formic acid were used for counting TCA-
precipitable radioactivity. For migration assays, cells seeded on type I collagen were 
incubated for one hour at 37°C before addition of 2.5 µg/ml mitomycin; After 24h, the 
confluent monolayer was scratched using a pipette tip and images were captured at the 
indicated times.  
 
Western blotting and immunoprecipitation 
Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to nitrocellulose membranes (GE Healthcare, UK). Blots were incubated for 
30 min in Tris-buffered saline containing 0.1% Tween 20 and 5% non-fat dry milk and 
further incubated for two hours (or overnight at 4°C) with the following antibodies: rabbit 
anti-ADAM12 (a gift from Dr. U. Wewer), rabbit anti-ILK (Cell Signaling Technology, 
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Boston, MA, USA) and monoclonal anti-β actin-peroxydase (Sigma Aldrich). Antibodies 
against phospho-Akt (Ser473), Phospho-GSK-3β (Ser9), total Akt , total GSK-3 and Alpha-
parvin (D7F9) were from Cell Signaling Technology. PINCH antibodies were from BD 
Transduction Laboratories. Bound antibodies were visualized with horseradish peroxidase–
conjugated antibodies using an enhanced chemiluminescence system (Millipore, Billerica, 
MA, USA). For immunoprecipitation, cell extracts were incubated with cross-linked ILK 
beads for 2 hrs at 4°C or preincubated for 1 hr with protein G sepharose beads (Amersham 
Biosciences) alone to reduce non-specific protein binding, followed by adsorption overnight 
to protein G sepharose beads pre-bound with 2 µg of specific or control ADAM12 rabbit IgG. 
The beads were washed five times and samples were analyzed by SDS-PAGE and 
immunoblotting. 
 
Expression of recombinant proteins 
pET102D-His-ADAM12 and pGEX-GST-ILK constructs were transformed in BL21-
DE3 (Novagen) and expression was induced by 0.25 mM isopropyl 1-thio-α-D-
galactopyranoside overnight at 18°C. Cells were harvested by centrifugation at 6,000 x g for 
15 minutes and lysed either in ice-cold PBS, pH 7.4 (137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4, 1.5 mM KH2PO4) for GST-ILK, or IMAC5 (20 mM Tris-HCl, pH 7.5, 500 mM 
NaCl, 5 mM imidazole) for His-ADAM12, and 0.1 mM AEBSF, complete EDTA-free 
protease inhibitor cocktail (Roche) and 1 mg/ml lysosyme. After 1hr incubation on ice and 2 
freeze/thaw cycles, the lysate was sonicated and clarified by centrifugation at 23,000 x g for 1 
hr at 4°C. His-ADAM12 was bound to Ni-charged Mag Beads (GenScript) for 1 hour at 4°C. 
After washing with 10 bed volumes of IMAC20 (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 20 
mM imidazole), the protein was eluted with IMAC 250 (20 mM Tris-HCl, pH 7.5, 500 mM 
NaCl, 250 mM imidazole) and dialysed against PBS. GST-ILK was bound to GST MagBeads 
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(GenScript) for 1 hr at 4°C. After washing with 10 bed volumes of WB 300 (50 mM Tris-HCl 
pH 8.0, 300 mM NaCl, 0.02% Tween 20, 0.1 mM AEBSF), the protein was eluted with 25 
mM gluthatione (Sigma Aldrich) in PBS. The GST tag was cleaved with thrombin (1 U/10 µg 
in 25 mM Tris-HCl pH 7.5, 1 mM DTT, 50 mM NaCl, 2.5 mM CaCl2) for 2 hrs at 30°C and 
immediately removed by chromatography on a GST MagBeads column. All protein fractions 
were concentrated on Ultracel YM 30 columns (Amicon) and stored at -80°C. 
 
Pull-down assays 
His-ADAM12 in IMAC5 was bound to Ni-charged Mag-Beads (Qiagen, Hilden, 
Germany), for 90 min at 4°C followed by three washes with IMAC5 buffer containing 5 mM 
imidazole, and incubated with ILK (w/w) for a 90 min incubation at 4°C. The nickel-agarose 
beads were further washed five times with 10 bed volumes of IMAC5 before elution with 
SDS-PAGE sample buffer. Samples were used for immunoblotting. 
 
Immunostaining and imaging 
To detect ADAM12, ILK and ITGB1 in HSCs, cells were plated on Permanox Lab-Tek 
chamber slides for 48 hrs with 2% FBS and fixed with 4% paraformaldehyde for 15 min. 
Cells were permeabilized with 0.1% Triton X-100 before incubation with rabbit anti-
ADAM12 (rb122), mouse anti-ILK (Santa Cruz Biotechnology, CA, USA), rabbit anti-ILK1 
(4G9) (Cell Signaling), mouse β1 integrin (Santa Cruz) or mouse anti-vinculin (Sigma, Saint-
Quentin, France) antibodies, followed by Alexa Fluor® 488-conjugated anti-mouse and 
Alexa Fluor® 555-conjugated anti-goat antibodies (Invitrogen, Karlsruhe, Germany), 
respectively. The slides were washed, mounted and viewed using an automated LEICA 
DMRXA2 microscope. 
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Relative quantifications of mRNA 
RT-qPCR was performed using the fluorescent dye SYBR Green methodology with the 
SybrTM Green I qPCRTM Core Kit (Eurogentec, Seraing, Belgium) and the ABI Prism 7700 
thermocycler (Perkin-Elmer, Foster city, CA, USA) as previously described (Le Pabic et al., 
2003). The following primer pairs were used for the indicated target genes, ADAM12L sense: 
5’-CACCATTGAAAAACTAAGGTGTGTG-3’, anti-sense: 5’-
GAGCCTGACAGGGTTGGAAG-3’; ADAM12S sense: 5’-CTGGGCACCTCCCTTCTGT-
3’, anti-sense: 5’-TGCTTCTGCTTGCCGGA-3’; Type I collagen, sense: 5’-
GGTCCTGATGGAAACAATGG-3’; anti-sense: 5’ TTCCACCTTGAACACCCTGT-3’; 
TGF-β sense: 5’-TGCGCTTGAGATCTTCAAACA-3’, anti-sense: 5’-
GGGCTAGTCGCACAGACCTC-3’; 18S rRNA sense : 5'-
CGCCGCTAGAGGTGAAATTC-3', anti-sense: 5'-TTGGCAAATGCTTTCGCTC-3'. 
 
In vitro kinase assays 
ILK immunoprecipitates were prepared using ILK antibodies cross-linked to magnetic 
Protein G Dynabeads (Invitrogen, Karlsruhe, Germany). Cell extracts were incubated with 
cross-linked ILK beads for 2 hrs at 4°C and successively washed with extraction buffer and 
kinase assay buffer. Kinase assays were performed by incubating ILK immunoprecipitates 
with 1 µg/ml GSK-3 crosstide peptide (Cell Signaling, Boston, MA, USA) for 30 min at 30°C 
in reaction buffer (1 mM dithiothreitol, 10 µM ATP, 1 µCi 32P-ATP, 0.01% Triton X-100, 25 
mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM MgCl2). The reaction was stopped by addition 
of SDS-PAGE sample buffer and samples were used for immunoblotting and autoradiography 
analysis. 
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Gene Name Description  Experiment Type   
ACTN2 Actinin, alpha 2 In vivo; in vitro; yeast 2-hybrid  
ACTN1 Actinin, alpha 1 In vivo; in vitro 
GRB2 Growth factor receptor-bound protein 2 In vivo 
SRC V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) In vivo; in vitro 
YES1 V-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 In vitro 
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) In vivo; in vitro  
PRKCE Protein kinase C, epsilon In vitro 
PRKCD Protein kinase C, delta Yeast 2-hybrid 
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29) In vitro 
SH3PXD2A SH3 and PX domains 2A In vivo; in vitro 
PACSIN3 Protein kinase C and casein kinase substrate in neurons 3 In vivo; in vitro; yeast 2-hybrid  
SH3D19 SH3 domain containing 19 In Vivo; in vitro; yeast 2-hybrid  
TGFBR2 Transforming growth factor, beta receptor II (70/80kDa) In Vivo; in vitro; yeast 2-hybrid  
GNB2L1 Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 In Vivo; in vitro; yeast 2-hybrid  
 
 
Table 1. List of ADAM12L-interacting proteins used as input for STRING application (http://string-db.org/). 
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FIGURE LEGENDS 
 
Figure 1. The ADAM12L protein interaction network. The list of the 14 proteins that 
physically bind ADAM12L (Table 1) was used as input in the STRING application and the 
graph was generated using default parameters. The interactions between ADAM12 and 
PRKCE (Sundberg et al., 2004), PRKCD (Asakura et al., 2002), GNB2L1 (Bourd-Boittin et 
al., 2008), TGFBR2 (Atfi et al., 2007) and between TGFBR2 and Src (Galliher and 
Schiemann, 2007) have not been entered in the database yet and were added manually (green 
connecting lines). 
 
Figure 2. ADAM12L interacts with ILK. Cell extracts from (A) Cos7 cells transfected with 
the long form of ADAM12, ADAM12L or (B) HSCs, were immunoprecipitated with anti-
ADAM12 or anti-ILK (IP) and immunoblotted with anti-ILK or anti-ADAM12 antibodies 
(IB). (C) Cos7 cells were transfected either with ADAM12L or the ADAM12-∆cyto 
cytoplasmic tail deletion or the short ADAM12S secreted form. Cell extracts were 
immunoprecipitated with anti-ILK and immunoblotted with anti-ADAM12 (right panel). The 
left panel shows immunoblots performed on crude extracts as controls. (D) Cos7 cells 
transfected with ADAM12L were immunoprecipitated with anti-ILK and immunoblotted (IB) 
with anti-PINCH, anti parvin or anti-ADAM12 antibodies. (E) ADAM12L, ADAM12S and 
ADAM12-∆cyto were expressed as His-tagged fusion proteins and binding assays were 
performed by incubating His-ADAM12 bound to nickel-agarose with 1 µg of purified ILK. 
Interacting proteins were immunoblotted with anti-ILK and anti-ADAM12 antibodies.  
 
Figure 3. ADAM12-L and ILK are recruited to focal adhesion structures upon β1 
integrin stimulation. HSCs were cultured on plastic dishes (-) or on dishes coated with type I 
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collagen (+) overnight in medium containing 2% FBS. Cell were immunostained with 
antibodies against anti-ADAM12, anti-ILK, anti-vinculin and anti-ITGB1 as indicated above 
the panels followed by TRITC or FITC-labeled secondary IgG. Representative fields are 
shown. Co-localization results in yellow cellular staining. (A) Localization of ADAM12 and 
ILK. (B) Localization of β1 integrin (ITGB1) and ADAM12. (C) Localization of vinculin and 
ΑDΑΜ12. (D) Localization of ILK and β1 integrin. (E) HSCs were pre-incubated with anti-
β1 integrin blocking antibodies or control mouse IgG1 before seeding on type I collagen. 
Scale bars: 10µm. 
 
Figure 4. RNAi-mediated decreased expression of ADAM12 in hepatic stellate cells 
induces actin cytoskeleton reorganization and loss of adhesion. HSCs were transfected 
with 2 nM non-targeted siRNA (Scr) or ADAM12L siRNA (siADAM12). After 48 hrs, 
Western blotting (A) and real-time PCR analyses (B) were used to confirm the efficiency and 
specificity of RNA interference in cell extracts. PCR controls included ADAM12S, Type I 
collagen (Col1) and TGF-β. (C) Transfected cells were analyzed by phase-contrast 
microscopy (left panels) and stained with rhodamine-conjugated phalloidin to monitor actin 
stress fibers (right panels). Nuclei were counterstained using DAPI (blue). (D) Cell adhesion 
was evaluated by counting adherent cells vs. cells released in the medium at 24 hr and 48 hr 
post-transfection. Results are expressed as the percentage of adherent cells and represented as 
the mean + s.d. of three independent experiments (* and #, p<0.05; **, p<0.01). Left panel: 
cell adhesion on plastic and collagen type I was compared 24 and 48 hrs post-transfection. 
Right panel, cell adhesion on different substrates was compared 24 hrs post-transfection. 
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Figure 5. Expression of ADAM12L augments phosphorylation of Akt and GSK-3. Cos7 
cells were transfected with empty vector (control) or ADAM12 constructs and cultured for 48 
hrs. The cells were then plated on dishes coated with type I collagen for the indicated times 
and the levels of phosphorylated Akt (Akt P-S473), phosphorylated GSK-3β (GSK3β P-S9), 
total Akt and GSK-3β were determined by western blot analysis (IB). Results are expressed 
as the mean + s.d. of three independent experiments (*, p<0.05; **, p<0.01; ***, p<0.01). (A) 
ADAM12L vs. control. (B) ADAM12L vs. the catalytically deficient ADAM12-E351Q 
mutant. (C) ADAM12L vs. ADAM12S and ADAM12-∆cyto (time = 60 min). 
 
Figure 6. Induction of Akt phosphorylation by ADAM12L expression requires ILK and 
stimulation of integrin β1 and PI3K activity. (A) Cos7 cells were co-transfected with 2 nM 
non-targeted siRNA (Scr) or ILK siRNA (siILK) and empty vector (control) or the ADAM12 
construct. Cells were cultured for 48 hrs, serum-starved and then plated on dishes coated with 
type I collagen for 1 hr. Levels of phosphorylated Akt (Akt-P-S473) were determined by 
western blot analysis (IB), immunoblots for ILK, ADAM12 and actin are shown as controls. 
(B) Cos7 cells were transfected with ADAM12 constructs, cultured for 48 hrs and incubated 
with anti-β1 integrin blocking antibodies for 30 min before plating on plastic dishes or dishes 
coated with type I collagen for 1 hr. Levels of phosphorylated Akt (Akt-P-S473) were 
determined by western blot analysis (IB), immunoblots for ILK, ADAM12 and actin are 
shown as controls. (C) Adhesion of HSCs on type I collagen augments phosphorylation of 
Akt and GSK-3. HSC cells were plated on dishes coated with type I collagen for the indicated 
times and the levels of phosphorylated Akt (Akt P-S473), phosphorylated GSK-3β (GSK3β P-
S9), total Akt and GSK-3β were determined by western blot analysis (IB). Immunoblots for 
endogenous ADAM12 and actin are shown as controls. (D) Cos7 cells were transfected with 
empty vector (control) or ADAM12L constructs and cultured for 48 hrs. The cells were then 
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incubated with the PI3K inhibitor Wortmannin (100 nM) or LY294002 (10 µM) and further 
plated on type I collagen-coated dishes for 1 hr. Levels of phosphorylated Akt (Akt-P-S473) 
were determined by western blot analysis (IB), immunoblots for ILK, ADAM12 and actin are 
shown as controls.  
 
Figure 7. ADAM12L expression induces GSK3 phosphorylation in ILK 
immunoprecipitates. Cos7 cell were transfected with (A) increasing amounts of ADAM12L 
or (B) empty vector (control), ADAM12L, ADAM12S, non-targeted siRNA (Scr) or ILK 
siRNA (siILK) in the presence of ADAM12L, as indicated. In vitro kinase assays were 
carried out by incubating ILK immunoprecipitated from the corresponding cell extracts with 
the GSK-3 crosstide peptide substrate (CT-GSK-3). Representative autoradiographs show the 
amount of 32P incorporation and results are expressed as the mean + s.d. of three independent 
experiments. 
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Supplementary Figure S1. ADAM12L interactions with ILK in Cos7 and LX2 cells. Cell 
extracts were prepared from Cos7 cells co-tranfected with the long form of ADAM12, 
ADAM12L and V5-tagged ILK, or from hepatic stellate LX2 cells transfected with V5-tagged 
ILK. Extracts were immunoprecipitated (IP) with anti-ADAM12 and immunoblotted (IB) with 
anti-V5. The precursor and processed (active) forms of ADAM12 correspond to the 110 and 90-
kDa species, respectively, detected by the antibody used.  
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Supplementary Figure S2: ADAM12 silencing in HSCs is associated with loss of cell 
adhesion without induction of cell death. HSCs were transfected with 2 nM non-targeted 
siRNA (Scr) or ADAM12L siRNA (siADAM12) for the indicated times. A) Protein extracts from 
cells collected in culture supernatants and from adherent cells were immunoblotted with anti-
ADAM12 antibodies (IB). Immunoblots for actin are shown as controls. Cell extracts from non-
transfected HSCs were used as control (HSC). B) Apoptosis was measured after 48 hrs of 
transfection by microscopic detection using Hoechst 33342 labeling (0.5 µg/ml). Cells with 
apoptotic nuclei were counted relative to the total population (n = 200). 
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Supplementary Figure S3: Overexpression of ADAM12 does not protect cells from 
Staurosprine- and TRAIL-induced cell death. Chinese hamster ovary (CHO) cells were 
transfected with ADAM12L or an empty vector (control). At 48 hours post transfection, cells are 
further treated for 24 hours with A) Staurosporine (0-1 µM) and B) Flag-tagged TRAIL (0-0.1 
µg/ml) from Alexis Biochemicals. A total of 2 µg/mL anti-Flag M2 (Sigma-Aldrich, Saint-
Quentin Fallavier, France) was added to induce TRAIL oligomerization. Cell viability was 
assessed by methylene blue staining. Data represent the mean ± SD from three independent 
experiments performed in sextuplet.  
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Supplementary Figure S4. Expression of ADAM12 favors cell proliferation and migration. 
Cos7 cells were transfected with empty vector (control) or ADAM12 constructs and cultured for 
48 hrs. The cells were then plated on dishes coated with type I collagen for the indicated times. 
(A) Cell proliferation was evaluated by 3[H]-thymidine incorporation. Results are expressed as 
the mean + s.d. of three independent experiments (*, p<0.05). (B) Cell migration was evaluated 
by the scratch wound-healing assay, in which a confluent cell monolayer is scratched with a 
pipette tip and the bare area is subsequently assessed for relocation of cells. Representative data 
from three independent experiments are shown and arrows indicate the width of the wound. 
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To Dr. Carl-Henrik Heldin, Editor 
Molecular Biology of the Cell 
 
Rennes, June 10, 2012 
 
 
 
Dear Pr. Heldin,  
 
I wish to thank you again for giving us the opportunity to submit a suitably revised version of 
our manuscript entitled “Identification of ILK as a new partner of the ADAM12 disintegrin and 
metalloprotease in cell adhesion and survival” by Leyme et al.  
 
 
We have carefully considered the points raised by the Reviewer 3 and we have addressed the three 
concerns, namely by making news experiments to improve microscopy pictures for Figure 4C and to 
reply to the questionable adhesion assays in Figure 4. These adhesion assays were clarified by adding 
a separated section in material and methods. Concerning the third point, the results for migration and 
proliferation assays, added to respond to the reviewer 2, were discussed and were now included as 
supplementary material.  
 
The changes made are listed in detail below. They include a number of clarifications, underlined in the 
revised manuscript, as well as changes in Figure 4C and D. 
 
We hope that our revised manuscript, which we believe brings important insights into the novel role of 
ADAM12 in cell survival pathway, will now be considered suitable for publication in Molecular 
biology of the cell. 
 
I wish to thank you again for your time and consideration. 
 
With all best regards, 
  
 
Nathalie Théret, Ph.D. 
 www.irset.org 
Reviewer #3 (Remarks to the Author): 
 
The manuscript reports the novel finding that ILK (integrin-linked kinase) associates with the 
cytoplasmic domain of the cell surface ADAM-12 metalloproteinase-disintegrin protein, and that 
these proteins co-localize in focal adhesions with β1 integrin upon binding of cells to collagen. The 
authors show that depletion of endogenous ADAM-12 in hepatic stellate cells (HSC) led to 
disorganization of actin stress fibers and affected adhesion to various matrices. Forced expression of 
ADAM-12 in Cos-7 cells that do not express endogenous ADAM-12 led to minor increases in cell 
proliferation (3H-thymidine) and cell migration (scratch wounding). ADAM-12 expression enhanced 
survival signalling through Akt and GSK-3 activation. All of these ADAM-12-dependent effects 
required the presence of the cytoplasmic domain and were independent of its metalloproteinase 
activity.This is an interesting, well-executed and well-written study. There is clear evidence to support 
the association of ILK and the ADAM-12 cytoplasmic domain, though it is not clear whether this is 
direct or indirect through some other shared components of the IPP or other integrin-associating 
proteins. It is a strength that the work uses both an over-expression model (Cos-7) and looks at the 
effects in a system that endogenously expresses ADAM-12. In answering the previous referees' 
criticisms the authors have included new experiments to analyse the effects of ADAM12 on cell 
proliferation and migration, and I think that these are now the weakest aspects of the revised 
manuscript. Overall the science is very good but there are a few specific issues remaining or 
introduced. 
 
 
Major points: 
 
Point 1. The effects of ADAM-12 knockdown on cytoskeletal organization in HSCs in Figure 4C 
are not particularly well documented. What has happened to the DAPI staining in the central (Scr) 
panel? Why are there DAPI stained nuclei apparent in the upper images that do not appear to 
correspond to any particular cell structures? The authors should improve these images to get the 
message across better. 
 
New immune-fluorescence studies were performed to improve the quality of the 
pictures. These new experiments replaced the previous one in figure 2C right panel in the 
revised manuscript. 
 
 
Point 2. Figure 4D is also problematic. ADAM-12 knockdown affects cell adhesion to multiple 
matrices (as might be expected for a β1 integrin-dependent mechanism), but I think the authors 
should not claim that there is a "reduced loss of cell adhesion on collagen, fibronectin and laminin 
compared to the albumin control". The effects are very minor and modest and it is surely better to 
simply say that adhesion was reduced compared to the Scr treatment. On a linked matter, the 
Materials and Methods do not adequately explain these adhesion assays. If they are conducted in the 
presence of serum, then effectively there will be a coating of fibronectin from the serum present; if 
there is no serum then I am surprised that there is so much binding to the plastic and albumin 
controls. The methods should therefore be described in a separate section of the Mats and Methods. 
 
We fully agree with the reviewer about this point that was not correctly documented in 
the manuscript. In figure 4D, experimental conditions were voluntary similar to that used for 
observation of cytoskeleton organization in ADAM12-knockdown cells that was 2% serum 
(figure 4C) as described in material and methods for immunostaining studies. In such 
conditions and in accordance with the comment of the reviewer, the presence of serum, even 
low, increased the background in all conditions including albumin coated dishes. Albeit 
significant, we agree that the reduced loss of adhesion on cell matrix is modest in such 
conditions.  
To definitively demonstrate the effect of matrices in rescuing the loss of adhesion in 
ADAM12 silenced cells, we performed three new independent experiments in complete 
absence of serum. Upon that condition, there was no adhesion on albumin as expected and the 
effect of collagen, fibronectin and laminin was significant compared with control (p<0.01).  
In order to homogenize our data, we also performed new kinetics of cell adhesion on 
type I collagen (figure 4D, left panel) using similar conditions, i.e. in free serum conditions. 
As expected, the loss of adhesion of knockdown ADAM12 cells compared to wild type was 
more stringent in absence of serum: 26%±0.25 and 40%± 2.7 instead of 15±5 and 37%±5, in 
presence of 2%FCS, for 24 and 48h, respectively. The type collagen again delayed this effect 
with a significant reduction of adhesion only after 48h (35.6±2.8 instead of 33%±5 when cells 
were cultured with 2% serum). Taken together, these new data did not change our conclusions 
described in the manuscript.  
These new experiments replaced the previous one in figure 2D (left and right panels) in 
the revised manuscript. Material and methods were modified to include a separated section for 
adhesion assay (page 19).  
 
 
Point 3. In Figure 5 using the ADAM-12-transfected Cos-7 cells, I think the authors are 
concluding too much from these data. Both the proliferation and migration effects are very minor, and 
are perhaps limited by the transfection efficiency into the Cos cells. Perhaps it might be better to look 
at random cell migration following transfection, where ADAM-12 negative and positive cells could be 
followed in the same field? Likewise I think the authors need something stronger to conclude an effect 
on proliferation, perhaps some cell cycle analyses of cells that are ADAM-12 positive versus negative. 
Alternatively perhaps these aspects could be downplayed in the manuscript, as it is likely that ADAM-
12/ILK interactions are not the main drivers of proliferation/migration in either model. 
 
The rational for exploring the effect of ADAM12 in cell proliferation and migration was based 
on the previous reported role of ILK in these processes. We agree with the reviewer about the minor 
effect observed in ADAM12 over-expressing cells but this fact was clearly indicated in the manuscript 
as “ a slight but significant increase in cell proliferation (Figure 5A) and migration (Figure 5B” 
In spite of repeated experiments and a high expression of ADAM12 in COS cells attesting the 
transfection efficiency, we never detected higher effects. However, our observations are in accordance 
with the literature since the effect of ADAM12L expression on cell proliferation depends on cell and 
culture conditions. Thus, ADAM12L expressing bronchial epithelial cell clones have been firstly 
shown more proliferative than wild-type cells (Rock et al., 2008), however stable ADAM12L over-
expressing epithelial breast cell clones and their wild type counterpart have similar proliferation rates 
in presence of estrogen (Roy &Moses, 2012). More importantly, using stable expressing cell clones, 
Roy et al. demonstrated that unlike the short ADAM12S form, over-expression of ADAM12L did not 
result in significant increase in cell migration and invasion (Roy et al. 2011).  
 
Taken together and as suggested by the reviewer, these observations support the fact that the 
full length ADAM12L is not a main driver of migration and that its role in proliferation is moderate 
and depends on cell type.  
According to this comment, we modified the text on page 10 to downplay the role of 
ADAM12L in cell proliferation and migration and we included the figure 5 in supplementary data 
(Figure 4S) rather in the full length paper: The sentence on page 10 was modified as follow: As shown 
in Figure S4, ADAM12 induced a slight but significant increase in cell proliferation (Figure S4A) and 
migration (Figure S4B) suggesting a minor effect in these conditions. In addition the text was 
modified in discussion to perspective our own data on Cos7 cell proliferation (pages 15 and 16).  
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Minor points 
 
• Scr not Src in Figure 8 
Done, thanks ! 
